publication date: Feb. 1, 2019
Issue 5 - Feb. 1, 2019
TCL45-05 (804 downloads)

  • 20-year follow-up data are in: Prostate cancer prevention works; concerns about high-grade disease dismissed

    Prostate cancer is the most common solid tumor in men. It has been estimated that 60-75 percent of men will have histologic evidence of prostate cancer during their lifetime and that 2-4 percent of men will die of the disease. African American men are at a greater risk of diagnosis and death.

  • Guest Editorial

    The Prostate Cancer Prevention Trial and nine lessons in prostate cancer medicine

    The publication by Ian M. Thompson and colleagues in last week’s New England Journal of Medicine regarding long term follow-up of patients in the NCI-sponsored Prostate Cancer Prevention Trial (PCPT) marks a good opportunity to review and reflect on the history of the trial and the past 30 years of prostate cancer medicine.

  • Real-World Evidence

    Gottlieb: FDA to expand real-world data infrastructure to enhance AI capabilities

    FDA is enhancing its ability to handle real-world evidence by training reviewers in data science via a curriculum on machine learning and artificial intelligence, said FDA Commissioner Scott Gottlieb.

  • Industry a no-show as Sens. Grassley and Wyden hold hearing on drug pricing

    Earlier this week, the Senate Committee on Finance convened what is likely to be the first in a series of hearings focused on the rising costs of prescription drugs, oncology drugs among them.

  • In Brief

    • Califano named physician-in-chief of Moores Cancer Center
    • NYU receives anonymous $75M gift to establish center for blood cancers
    • Ross Mitchell named artificial intelligence officer at Moffitt
    • Sagar Lonial awarded Gray Family Chair in Cancer at Winship
    • Silvia Formenti and Heather McArthur awarded SU2C Laura Ziskin Prize
    • Helen Heslop named by SU2C to lead ‘Dream Team’
    • Robert Prins receives grant to research brain tumor treatments
    • Johns Hopkins Greenberg Bladder Cancer Institute Awards focused on bladder cancer in women
    • ASCO names advance of the year: progress in treating rare cancers

  • TCCL Logo

  • Trials & Tribulations

    Glioblastoma patient is first to receive treatment under Right to Try. Our question is Why?

    A University of California, Irvine patient with glioblastoma recently received an experimental cancer vaccine from the U.S. subsidiary of Brussels-based Epitopoietic Research Corp. (ERC-USA). While most cases of patients receiving experimental medical treatment are not particularly newsworthy, this one was.

  • Clinical Roundup

    • Study incorporates patient feedback into better cancer treatments
    • Patients getting placebo allowed to cross to Erleada as TITAN results unblinded
    • Antioxidants may enhance chemotherapy treatment for brain tumor

  • Drugs & Targets

    • Lung-MAP precision medicine trial expands
    • Alimta + Keytruda and platinum chemo for NSCLC gets FDA label expansion
    • Trovagene and PoC Capital agree to fund clinical development of onvansertib in metastatic colorectal cancer

Copyright (c) 2019 The Cancer Letter Inc.

Back to top